TNF-alpha blockers in inflammatory bowel diseases: practical recommendations and a user's guide: an update
M Vulliemoz, S Brand, P Juillerat, C Mottet… - Digestion, 2020 - karger.com
Background: Anti-tumour necrosis factor-alpha (anti-TNF) antagonists have been the
mainstay in the treatment of inflammatory bowel diseases (IBDs) for over 20 years …
mainstay in the treatment of inflammatory bowel diseases (IBDs) for over 20 years …
Mechanism-based treatment strategies for IBD: cytokines, cell adhesion molecules, JAK inhibitors, gut flora, and more
P Schreiner, MF Neurath, SC Ng, EM El-Omar… - Inflammatory intestinal …, 2019 - karger.com
Background: Although TNF inhibitors revolutionized the therapy of inflammatory bowel
disease (IBD), we have been reaching a point where other therapies with different …
disease (IBD), we have been reaching a point where other therapies with different …
Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease
R Atreya, MF Neurath - The lancet Gastroenterology & hepatology, 2018 - thelancet.com
Biological therapy has led to marked improvements in treatment of patients with
inflammatory bowel disease, and an increasing number of drugs has been approved for …
inflammatory bowel disease, and an increasing number of drugs has been approved for …
Mucosal IL13RA2 expression predicts nonresponse to anti‐TNF therapy in Crohn's disease
B Verstockt, S Verstockt, B Creyns… - Alimentary …, 2019 - Wiley Online Library
Background Ileocolonic expression of IL13RA2 has been identified as a predictive marker
for nonresponsiveness to infliximab (IFX) in patients with Crohn's disease (CD). Aim To …
for nonresponsiveness to infliximab (IFX) in patients with Crohn's disease (CD). Aim To …
Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease
H Schmitt, U Billmeier, W Dieterich, T Rath… - Gut, 2019 - gut.bmj.com
Objective Anti-tumour necrosis factor (TNF) antibodies are successfully used for treatment of
Crohn's disease. Nevertheless, approximately 40% of patients display failure to anti-TNF …
Crohn's disease. Nevertheless, approximately 40% of patients display failure to anti-TNF …
Future biologic targets for IBD: potentials and pitfalls
GY Melmed, SR Targan - Nature reviews Gastroenterology & …, 2010 - nature.com
The treatment of patients with IBD has evolved towards biologic therapy, which seeks to
target specific immune and biochemical abnormalities at the molecular and cellular level …
target specific immune and biochemical abnormalities at the molecular and cellular level …
Cytokines in inflammatory bowel diseases–update 2020
M Leppkes, MF Neurath - Pharmacological Research, 2020 - Elsevier
Abstract Inflammatory Bowel Diseases (IBD), namely Crohn's Disease and Ulcerative Colitis,
cause a significant disease burden in modern civilization. Ever since the introduction of anti …
cause a significant disease burden in modern civilization. Ever since the introduction of anti …
Precision medicine in IBD: genes, drugs, bugs and omics
R Mao, M Chen - Nature Reviews Gastroenterology & Hepatology, 2022 - nature.com
Key studies published in 2021 demonstrated mechanisms that drive macrophage–fibroblast
pathogenicity in Crohn's disease, developed multi-omics profiles to predict response to …
pathogenicity in Crohn's disease, developed multi-omics profiles to predict response to …
Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target
Inflammatory bowel diseases (IBD) are chronic, relapsing, and destructive inflammatory
disorders of the gastrointestinal tract. Both Crohn's disease (CD) and ulcerative colitis (UC) …
disorders of the gastrointestinal tract. Both Crohn's disease (CD) and ulcerative colitis (UC) …
Adverse effects of biologics used for treating IBD
In the last decade, biologic agents, in particular anti-TNF agents such as infliximab,
adalimumab, and certolizumab have substantially extended the therapeutic armamentarium …
adalimumab, and certolizumab have substantially extended the therapeutic armamentarium …